BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24370899)

  • 1. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer.
    Huang SJ; Wang YF; Jin ZY; Sun JY; Guo ZL
    Tumour Biol; 2014 May; 35(5):4023-9. PubMed ID: 24370899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer.
    Gao H; Ge RC; Liu HY; Wang Y; Yan S
    Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.
    Zhao X; Zhang Z; Yuan Y; Yuan X
    Tumour Biol; 2014 Aug; 35(8):8335-41. PubMed ID: 24859833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer.
    Du Y; Su T; Zhao L; Tan X; Chang W; Zhang H; Cao G
    PLoS One; 2014; 9(6):e99843. PubMed ID: 24933103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.
    Shi ZH; Shi GY; Liu LG
    Int J Clin Exp Pathol; 2015; 8(3):3132-7. PubMed ID: 26045829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A miR-15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum-based chemotherapy.
    Xue P; Zhang G; Zhang H; Cui S; Zhang L; Yu T; Xiao M; Li L; Lu X
    J Cell Mol Med; 2022 Nov; 26(21):5439-5451. PubMed ID: 36181289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
    Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
    Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
    Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
    Ganzinelli M; Linardou H; Alvisi MF; Caiola E; Lo Russo G; Cecere FL; Bettini AC; Psyrri A; Milella M; Rulli E; Fabbri A; De Maglie M; Romanelli P; Murray S; Broggini M; Marabese M; Garassino MC
    ESMO Open; 2021 Feb; 6(1):100034. PubMed ID: 33422766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
    Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
    Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
    Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy].
    Wang J; Zhang Q; Zhang H; Wang Q; Yang X; Gu Y; Zhang S
    Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):337-41. PubMed ID: 20677561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
    Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
    Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.